Alterity Therapeutics, a biotechnology company specializing in treatments for neurodegenerative diseases, announced that its CEO, David Stamler, M.D., will present at the MST Access 'Hidden Gems in Life Sciences' webinar. The presentation is scheduled for June 13, 2024, in Australia and June 12, 2024, in the United States. The company, which is in the clinical stage of developing its lead asset, ATH434, for treating Parkinsonian disorders, will offer an overview of its operations and developments. Investors will have the opportunity to ask questions during the webinar, and a recording will be available on Alterity's website post-event. The announcement was authorized by CEO David Stamler and is part of a Form 6-K report filed with the SEC, which is also incorporated by reference into the company's various registration statements.

Alterity Therapeutics, a biotechnology company specializing in treatments for neurodegenerative diseases, announced that its CEO, David Stamler, M.D., will present at the MST Access 'Hidden Gems in Life Sciences' webinar. The presentation is scheduled for June 13, 2024, in Australia and June 12, 2024, in the United States. The company, which is in the clinical stage of developing its lead asset, ATH434, for treating Parkinsonian disorders, will offer an overview of its operations and developments. Investors will have the opportunity to ask questions during the webinar, and a recording will be available on Alterity's website post-event. The announcement was authorized by CEO David Stamler and is part of a Form 6-K report filed with the SEC, which is also incorporated by reference into the company's various registration statements.